9:32 AM
 | 
Jun 06, 2018
 |  BC Innovations  |  Translation in Brief

JAKs and clots

Brigham and Women’s team suggest JAK-2 inhibitors could treat thrombosis

Brigham and Women’s Hospital researchers have uncovered the mechanisms behind a major complication in bone marrow disorders by linking a JAK-2 mutation with thrombosis in patients and mice, and identified a way to treat blood clotting by inhibiting JAK-2.

The Science Translational Medicine study connected a known Janus kinase-2 (JAK-2) mutation found in patients with myeloproliferative neoplasms (MPNs) to thrombosis caused by increased formation of neutrophil extracellular traps (NETs) -- a component of innate immunity -- and suggested JAK inhibition could extend beyond patients with MPN to treat thrombosis.

Patients with MPNs -- bone marrow stem cell disorders characterized by high numbers of differentiated blood cells -- are at risk for developing thromboembolic blood clotting, but the mechanisms underlying thrombosis in the disorder are unknown....

Read the full 601 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >